Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CPT Pharmacometrics Syst Pharmacol
Hlavní autoři: Sokolov, Victor, Yakovleva, Tatiana, Chu, Lulu, Tang, Weifeng, Greasley, Peter J., Johansson, Susanne, Peskov, Kirill, Helmlinger, Gabriel, Boulton, David W., Penland, Robert C.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7180004/
https://ncbi.nlm.nih.gov/pubmed/32064793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12498
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky